Compile Data Set for Download or QSAR
Report error Found 75 for UniProtKB: Q15075
LigandPNGBDBM751700(9-(1-methyl-1H-pyrazol-3-yl)-2-morpholino-N-(pyrid...)
Affinity DataIC50: 55nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751676(5-methoxy-2-morpholino-N-(pyridin-4-yl)-6-(3-(pyri...)
Affinity DataIC50: 55nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751699(2-di(pyridin-4-yl)pyrimidin-4-amine | US202501973...)
Affinity DataIC50: 55nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751674(5-methoxy-6-(2-(1-methyl-H-pyrazol-3-yl)pyridin-4-...)
Affinity DataIC50: 55nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751663(5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-2...)
Affinity DataIC50: 55nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751728(azetidin-1-yl[4-[3-(1-methylpyrazol-3-yl)phenyl]-2...)
Affinity DataIC50: 55nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751677(5-methoxy-6-(5-(1-methyl-1H-pyrazol-3-yl)pyridazin...)
Affinity DataIC50: 55nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751667(5-methoxy-6-(5-(1-methyl-1H-pyrazol-3-yl)pyridin-3...)
Affinity DataIC50: 55nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751732(N-[2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]decan-8...)
Affinity DataIC50: 55nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751694(5-methoxy-6-(3-(1-methyl-H-pyrazol-3-yl)phenyl)-N-...)
Affinity DataIC50: 55nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751714(5-methoxy-2-morpholino-6-(3-(oxazol-2-yl)phenyl)-N...)
Affinity DataIC50: 55nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751713(2-di(pyridin-4-yl)pyrimidin-4-amine | US202501973...)
Affinity DataIC50: 55nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751669(6-methoxy-6-(3-(3-methyl-1H-pyrazol-1-yl)phenyl)-2...)
Affinity DataIC50: 55nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751675(4-(3-(5-methoxy-2-morpholino-6-(pyridin-4-ylamino)...)
Affinity DataIC50: 550nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751722(5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)phenyl)-N...)
Affinity DataIC50: 550nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751698(9-(1-methyl-1H-pyrazol-3-yl)-2-morpholino-N-(pyrid...)
Affinity DataIC50: 550nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751673(6-(3,4-dimethoxyphenyl)-5-methoxy-2-morpholino-N-(...)
Affinity DataIC50: 550nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751731(6-methyl-9-(1-methylpyrazol-3-yl)-2-morpholino-4-(...)
Affinity DataIC50: 550nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751680(US20250197375, Compound 20)
Affinity DataIC50: 550nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751679(US20250197375, Compound 19)
Affinity DataIC50: 550nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751726(N,N-dimethyl-4-[3-(1-methylpyrazol-3-yl)phenyl]-2-...)
Affinity DataIC50: 550nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751701(6-(3-(1,4-dimethyl-1H-pyrazol-3-yl)phenyl)-6-metho...)
Affinity DataIC50: 550nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751711(6-(5,6-dimethoxypyridin-2-yl)-5-methoxy-2-morpholi...)
Affinity DataIC50: 550nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751668(6-(3-(1H-pyrazol-1-yl)phenyl)-5-methoxy-2-morpholi...)
Affinity DataIC50: 550nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751710(6-(3-(1H-pyrazol-1-yl)phenyl)-5-chloro-2-morpholin...)
Affinity DataIC50: 550nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751709(9-(1-methyl-1H-pyrazol-3-yl)-2-morpholino-N-(pyrid...)
Affinity DataIC50: 550nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751734(6-[3-(1-methylpyrazol-3-yl)phenyl]-2-morpholino-5-...)
Affinity DataIC50: 550nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751708(1-(3-(5-methoxy-2-morpholino-6-(pyridin-4-ylamino)...)
Affinity DataIC50: 550nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751685(5-methoxy-6-(2-(1-methyl-1H-pyrazol-3-yl)pyridin-4...)
Affinity DataIC50: 550nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751707(5-methoxy-6-(3-(4-methoxy-1-methyl-1H-pyrazol-3-yl...)
Affinity DataIC50: 550nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751718(4-(5-methoxy-4-(3-(1-methyl-1H-pyrazol-3-yl)phenyl...)
Affinity DataIC50: 550nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751672(US20250197375, Compound 12)
Affinity DataIC50: 550nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751717(5-methoxy-2-morpholino-65-(pyridazin-3-yl)pyridin-...)
Affinity DataIC50: 550nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751693(N,N-dimethyl-2-morpholino-4-(3-pyrazol-1-ylphenyl)...)
Affinity DataIC50: 550nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751716(5-methoxy-2'-(I-methyl-1H-pyrazol-3-yl)-2-morpholi...)
Affinity DataIC50: 550nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751670(US20250197375, Compound 10)
Affinity DataIC50: 550nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751697(4-[5-methoxy-4-morpholino-6-(3-pyrazol-1-ylphenyl)...)
Affinity DataIC50: 5.50E+3nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751664(pyrimidin-4-yl)morpholine | US20250197375, Compou...)
Affinity DataIC50: 5.50E+3nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751705(oxide | US20250197375, Compound 45)
Affinity DataIC50: 5.50E+3nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751662(morpholine | US20250197375, Compound 2)
Affinity DataIC50: 5.50E+3nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751661(5-methoxy-2-morpholino-N-phenyl-6-(1-phenyl-1H-pyr...)
Affinity DataIC50: 5.50E+3nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751703(pyrimidin-2-yl)morpholin-3-yl)methanol | US202501...)
Affinity DataIC50: 5.50E+3nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751702((R)-5-methoxy-6-(3-(1-methyl-1H-pyrazol-3-yl)pheny...)
Affinity DataIC50: 5.50E+3nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751690(4-(5-methoxy-4-(3-(1-methyl-1H-pyrazol-3-yl)phenyl...)
Affinity DataIC50: 5.50E+3nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751689(1-(3-(5-methoxy-2-morpholino-6-(pyridin-3-ylamino)...)
Affinity DataIC50: 5.50E+3nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751688(4-(3-(5-methoxy-2-morpholino-6-(pyridin-3-ylamino)...)
Affinity DataIC50: 5.50E+3nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751687(4-(3-(5-methoxy-2-morpholino-6-(pyridin-3-ylamino)...)
Affinity DataIC50: 5.50E+3nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751686(1-(3-(5-methoxy-2-morpholino-6-(pyridin-3-ylamino)...)
Affinity DataIC50: 5.50E+3nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751733(US20250197375, Compound 73)
Affinity DataIC50: 5.50E+3nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

LigandPNGBDBM751684(US20250197375, Compound 24)
Affinity DataIC50: 5.50E+3nMAssay Description:Genetic or pharmacological disruption of PIKfyve activity results in enlargement of endosomal vesicles. This enlargement was utilized as a surrogate ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
10/14/2025
Entry Details
Go to US Patent

Displayed 1 to 50 (of 75 total ) | Next | Last >>
Jump to: